Cambrex Reports Third Quarter 20...(8 ...),Health

Date:11/3/2009

8 -------------- ------------- % of % of Amount Sales Amount Sales -------------- ------------- Gross Sales $177,568 100.0% $184,440 100.0% Allowances and Rebates 623 0.4% 1,137 0.6% -------- ------- Net Sales 176,945 99.6% 183,303 99.4% Other Revenues (262) -0.1% 1,792 1.0% -------- ------- Net Revenues 176,683 99.5% 185,095 100.4% Cost of Goods Sold 120,919 68.1% 127,120 69.0% -------- ------- Gross Profit 55,764 31.4% 57,975 31.4% Operating Expenses Selling, General and Administrative Expenses 26,889 15.2% 31,511 17.0% Research and Development Expenses 5,924 3.3% 5,945 3.2% Restructuring Expenses - 0.0% 1,469 0.8% Strategic Alternative Costs - 0.0% 1,408 0.8% -------- ------- Total Operating Expenses 32,813 18.5% 40,333 21.8% -------- ------- Operating Profit 22,951 12.9% 17,642 9.6% Other Expenses/(Income): Interest Expense, net 3,410 1.9% 2,302 1.3% Other (Income)/Expense, net (139) -0.1% 459 0.2% -------- ------- Income Before Income Taxes 19,680 11.1% 14,881 8.1% Provision fo
'/>"/>

SOURCE Cambrex Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
2. Cambrex to Announce Third Quarter 2009 Financial Results on November 3, 2009
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA